RESUMO
Image-guided radiotherapy (IGRT), based on radiopaque markers placed in the prostate gland, was used for proton therapy of prostate patients. Orthogonal X-rays and the IBA Digital Image Positioning System (DIPS) were used for setup correction prior to treatment and were repeated after treatment delivery. Following a rationale for margin estimates similar to that of van Herk,(1) the daily post-treatment DIPS data were analyzed to determine if an adaptive radiotherapy plan was necessary. A Web application using ASP.NET MVC5, Entity Framework, and an SQL database was designed to automate this process. The designed features included state-of-the-art Web technologies, a domain model closely matching the workflow, a database-supporting concurrency and data mining, access to the DIPS database, secured user access and roles management, and graphing and analysis tools. The Model-View-Controller (MVC) paradigm allowed clean domain logic, unit testing, and extensibility. Client-side technologies, such as jQuery, jQuery Plug-ins, and Ajax, were adopted to achieve a rich user environment and fast response. Data models included patients, staff, treatment fields and records, correction vectors, DIPS images, and association logics. Data entry, analysis, workflow logics, and notifications were implemented. The system effectively modeled the clinical workflow and IGRT process.
Assuntos
Internet , Neoplasias da Próstata/radioterapia , Terapia com Prótons , Radioterapia Guiada por Imagem/métodos , Software , Fluxo de Trabalho , Humanos , Masculino , Neoplasias da Próstata/diagnóstico , Radioterapia de Alta Energia/métodosRESUMO
PURPOSE: Pencil-beam scanning (PBS) is a modern delivery technique used in proton beam therapy (PBT) to reduce normal tissue reactions. No dosimetric correlation between dermatitis and PBS has been reported for breast cancer. The current study aimed to investigate the factors associated with grade 2 or higher dermatitis in patients with breast cancer undergoing PBT using PBS. METHODS: The medical data of 42 patients with breast cancer who underwent adjuvant radiotherapy between December 2019 and September 2023 were reviewed. All patients received hypofractionated radiotherapy (HFRT), either 26 Gy (relative biological effectiveness [RBE])/five fractions or 40.05 or 43.5 Gy (RBE)/15 fractions, for the whole breast/chest wall with or without nodal irradiation. The duration of acute radiation dermatitis was defined as within 90 days from the start of radiotherapy. The Kaplan-Meier method and Cox proportional hazards model were used for univariate and multivariate analyses of the actuarial rates of grade 2-3 dermatitis. RESULTS: Twenty-two (52.4%) and 20 (47.6%) patients were diagnosed with grade 1 and 2 dermatitis, respectively. Multivariate analysis revealed a clinical target volume (CTV) ≥ of 320 cc (p = 0.035) and a skin dose of D10cc ≥ 38.3 Gy (RBE) (p = 0.009) as independent factors of grade 2 dermatitis. The 10-week cumulative grade 2 dermatitis rates were 88.2%, 39.4%, and 8.3% (p < 0.001) for patients with both high, either high, and neither high CTV and D10cc, respectively. CONCLUSION: To the best of our knowledge, this is the first study on dosimetric correlations for dermatitis in patients with breast cancer who underwent hypofractionated PBT using PBS. In the era of HFRT, skin dose modulation using PBS may reduce the incidence of dermatitis.
RESUMO
BACKGROUND: To review treatment toxicity for patients with pancreatic and ampullary cancer treated with proton therapy at our institution. MATERIAL AND METHODS: From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma. Two patients with unresectable disease were excluded from the analysis for reasons unrelated to treatment. Proton doses ranged from 50.40 cobalt gray equivalent (CGE) to 59.40 CGE. RESULTS: Median follow-up for all patients was 11 (range 5-36) months. No patient demonstrated any grade 3 toxicity during treatment or during the follow-up period. Grade 2 gastrointestinal toxicities occurred in three patients, consisting of vomiting (n = 3); and diarrhea (n = 2). Median weight loss during treatment was 1.3 kg (1.75% of body weight). Chemotherapy was well-tolerated with a median 99% of the prescribed doses delivered. Percentage weight loss was reduced (p = 0.0390) and grade 2 gastrointestinal toxicity was eliminated (p = 0.0009) in patients treated with plans that avoided anterior and left lateral fields which were associated with reduced small bowel and gastric exposure. DISCUSSION: Proton therapy may allow for significant sparing of the small bowel and stomach and is associated with a low rate of gastrointestinal toxicity. Although long-term follow-up will be needed to assess efficacy, we believe that the favorable toxicity profile associated with proton therapy may allow for radiotherapy dose escalation, chemotherapy intensification, and possibly increased acceptance of preoperative radiotherapy for patients with resectable or marginally resectable disease.
Assuntos
Adenocarcinoma/terapia , Ampola Hepatopancreática , Quimiorradioterapia/efeitos adversos , Neoplasias do Ducto Colédoco/terapia , Desoxicitidina/análogos & derivados , Fluoruracila/análogos & derivados , Gastroenteropatias/epidemiologia , Neoplasias Pancreáticas/terapia , Terapia com Prótons/efeitos adversos , Adenocarcinoma/epidemiologia , Adenocarcinoma/patologia , Administração Oral , Idoso , Ampola Hepatopancreática/efeitos dos fármacos , Ampola Hepatopancreática/patologia , Ampola Hepatopancreática/efeitos da radiação , Capecitabina , Neoplasias do Ducto Colédoco/epidemiologia , Neoplasias do Ducto Colédoco/patologia , Desoxicitidina/administração & dosagem , Desoxicitidina/efeitos adversos , Esquema de Medicação , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/efeitos adversos , Gastroenteropatias/etiologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/epidemiologia , Neoplasias Pancreáticas/patologia , Terapia com Prótons/métodos , Lesões por Radiação/epidemiologia , Dosagem Radioterapêutica , Estudos RetrospectivosRESUMO
Purpose: This study aimed to quantitatively evaluate the range uncertainties that arise from daily cone-beam CT (CBCT) images for proton dose calculation compared to CT using a measurement-based technique. Methods: For head and thorax phantoms, wedge-shaped intensity-modulated proton therapy (IMPT) treatment plans were created such that the gradient of the wedge intersected and was measured with a 2D ion chamber array. The measured 2D dose distributions were compared with 2D dose planes extracted from the dose distributions using the IMPT plan calculated on CT and CBCT. Treatment plans of a thymoma cancer patient treated with breath-hold (BH) IMPT were recalculated on 28 CBCTs and 9 CTs, and the resulting dose distributions were compared. Results: The range uncertainties for the head phantom were determined to be 1.2% with CBCT, compared to 0.5% for CT, whereas the range uncertainties for the thorax phantom were 2.1% with CBCT, compared to 0.8% for CT. The doses calculated on CBCT and CT were similar with similar anatomy changes. For the thymoma patient, the primary source of anatomy change was the BH uncertainty, which could be up to 8 mm in the superior-inferior (SI) direction. Conclusion: We developed a measurement-based range uncertainty evaluation method with high sensitivity and used it to validate the accuracy of CBCT-based range and dose calculation. Our study demonstrated that the CBCT-based dose calculation could be used for daily dose validation in selected proton patients.
RESUMO
Radiation-induced emesis (RIE) is usually noted during abdominal-pelvic radiotherapy. In gynecological malignancies, it is usually noted in para-aortic but not whole-pelvic irradiation. Irradiated small bowel (SB) may be associated with RIE. The significance of SB dosimetry remains unclear. Dosimetric and non-dosimetric factors were evaluated and correlated with RIE in 45 patients with gynecological malignancies undergoing extended-field radiotherapy (EFRT) (median 45 Gy) from 2006 to 2021. Early-onset RIE (within 72 h after the first fraction of EFRT) was noted in 10 of 12 RIE patients. RIE was significantly associated with the SB mean dose. The RIE rates were 58.3% and 15.2% (p = 0.007) in patients with a low (<63%) and high (≥63%) SB mean dose. Logistic regression revealed that the SB mean dose remained the independent factor of overall RIE (p = 0.049) and early-onset RIE (p = 0.014). Therefore, constraint of the SB mean dose limited to less than 63% of the prescribed dose is suggested to decrease RIE.
Assuntos
Neoplasias do Colo do Útero , Feminino , Humanos , Pelve , Vômito/etiologiaRESUMO
PURPOSE: To commission MCsquare (a multi-cores CPU-based dose calculation engine) for pencil beam scanning (PBS) proton therapy, integrate it into RayStation treatment plan system (TPS) to create a dedicated platform for fast independent dose verification. METHOD: A MCsquare-based independent dose verification platform (MC2InRS) was developed to realize automatic dose re-calculation for clinical use, including data preparation, dose calculation, 2D/3D gamma analysis. MCsquare was commissioned based on in-air lateral dose profiles, integrated depth dose, and the absolute dose of different beam energies for Proteus®ONE. MC2InRS was validated with measurement data using various targets and depths in a water phantom. This study also investigated 15 clinical cases to demonstrate the feasibility and effectiveness of MC2InRS platform in clinic practice. RESULTS: Between simulation and measurement, the distal range differences at 80% (R80) and 20% (R20) dose levels for each energy were below 0.05 mm, and 0.1 mm, respectively, and the absolute dose differences were below 0.5%. 29 out of 36 QA planes reached a 100% gamma passing rate (GPR) for 2%/2mm criteria, and a minimum of 98.3% gamma was obtained in water phantom between simulation and measurement. For the 15 clinical cases investigated, the average 2D GPR (2%/2mm) was 95.4%, 99.3% for MCsquare vs. measurement, MCsquare vs. TPS, respectively. The average 3D GPR (2%/2mm) was 98.9%, 95.3% for MCsquare vs. TPS in water, and computed tomography (CT), respectively. CONCLUSION: MC2InRS, a fast, independent dose verification platform, has been developed to perform dose verification with high accuracy and efficiency for Pencil Bream Scanning (PBS). Its potential to be applied in routine clinical practice has also been discussed.
Assuntos
Neoplasias Encefálicas/radioterapia , Neoplasias de Cabeça e Pescoço/radioterapia , Neoplasias da Próstata/radioterapia , Terapia com Prótons , Planejamento da Radioterapia Assistida por Computador/métodos , Algoritmos , Simulação por Computador , Estudos de Viabilidade , Humanos , Masculino , Imagens de Fantasmas , Terapia com Prótons/métodos , Dosagem Radioterapêutica , Tomografia Computadorizada por Raios X , ÁguaRESUMO
BACKGROUND & PURPOSE: Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. MATERIALS AND METHODS: We reviewed patients with skull-base chordoma or chondrosarcoma treated with proton-based therapy between 2007 and 2018. We analyzed 148 patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1 cm3 of the anterior optic pathway. Eyes were classified as "functionally blind" if visual acuity was 20/200 or worse. Kaplan-Meier and normal tissue complication probability modeling were used to establish the relationship between radiation dose and risk of functional vision loss. RESULTS: At last follow-up, 110 of 148 patients were alive with no evidence of disease progression. With a median follow-up of 4.1 years (range, 0.5-12.8), 5 eyes in 3 patients developed functional blindness, with 2 patients developing bilateral blindness. Median time to blindness was 15.2 months. The 5-year incidence of vision loss was 2.1% (95% CI: 0.9-4.9%). On univariate analysis, development of blindness was associated with presence of multiple medical comorbidities (p = 0.0040). While there were no events with a maximum dose < 60GyRBE delivered to the anterior optic pathway, the crude rate was 3.6% over 60GyRBE, with all events occurring between 60-65GyRBE. CONCLUSIONS: Despite the high radiotherapy dose delivered to patients with skull-base chordoma and chondrosarcoma, the rate of vision loss is low and no events occurred in those who received a maximum dose under 60GyRBE.
Assuntos
Condrossarcoma , Cordoma , Terapia com Prótons , Neoplasias da Base do Crânio , Cegueira , Condrossarcoma/radioterapia , Cordoma/radioterapia , Humanos , Terapia com Prótons/efeitos adversos , Prótons , Crânio , Neoplasias da Base do Crânio/radioterapiaRESUMO
In terms of dose distribution, protons are more sensitive to range variations than photons due to their unique properties. The aim of this study was to develop a method to identify patient-specific robust proton beam angles for lung tumor irradiation by investigating the association between water equivalent thickness (WET) variation and inter-fraction motion-induced target dose degradation. Using 3-dimensional computed tomography (3D-CT) images, the impact of WET variations on the target dose coverage of a series of coplanar proton beams was evaluated for 4 patients with lung cancer. Using ray tracing, WET maps, or WET baseline, were estimated for the internal target volume (ITV) at every 5° gantry interval in the axial plane. After calculating the WET baseline, the planning CT was shifted 5 mm in each anterior-posterior (AP), superior-inferior (SI), and left-right (LR) direction, yielding a total of 6 shifted CTs, and differential WET maps between the planning CT and each shifted CT were calculated. Target dose differences were associated with the average WET change between the original planning CT and the shifted CTs for all 360° gantry rotation beams. Target and OAR dose metrics in the ΔWET-guided plans were compared with those of the clinical plans. The WET variation maps showed areas of both high and low WET variations, with overall similar patterns yet individual differences reflecting tumor position differences. For all 4 patients investigated in this study, the coplanar plans demonstrated a strong correlation between WET changes and ITV dose reductions. Target dose coverage was more stable with the ΔWET-guided plan while OAR doses were comparable to the clinical plan. The WET variation maps have been used in this pilot study to identify proton beam angles that are either sensitive or robust to WET changes in proton passive scattering. This work demonstrates the feasibility of using WET variation maps to assist the planner in inter-fraction motion-robust proton beam angle selection.
Assuntos
Fracionamento da Dose de Radiação , Neoplasias Pulmonares/radioterapia , Terapia com Prótons/métodos , Planejamento da Radioterapia Assistida por Computador , Algoritmos , Tomografia Computadorizada Quadridimensional , Humanos , Modelos Teóricos , Movimento (Física) , Terapia com Prótons/normas , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Planejamento da Radioterapia Assistida por Computador/normas , Radioterapia Guiada por ImagemRESUMO
PURPOSE: Mean heart dose (MHD) correlates with late cardiac toxicity among survivors of lymphoma receiving involved-field radiation therapy (IFRT). We investigated MHD and cardiac substructure dose across older and newer radiation fields and techniques to understand the value of evaluating MHD alone. METHODS AND MATERIALS: After institutional review board approval, we developed a database of dosimetry plans for 40 patients with mediastinal lymphoma, which included IFRT (anterior-posterior and posterior-anterior), involved-site radiation therapy (ISRT) + 3-dimensional conformal radiation therapy (3DCRT), ISRT + intensity modulated radiation therapy, and ISRT + proton therapy plans for each patient. Each plan was evaluated for dose to the heart and cardiac substructures, including the right and left ventricles (RV, LV) and atria (RA, LA); tricuspid, mitral (MV), and aortic valves; and left anterior descending coronary artery (LAD). Correlation between MHD and cardiac substructure dose was assessed with linear regression. A correlation was considered very strong, strong, moderate, or weak if the r was ≥0.8, 0.6-0.79, 0.4-0.59, or <0.4, respectively. RESULTS: A very strong correlation was observed between MHD and the mean cardiac substructure dose for each plan as follows: IFRT-LV, RV, LA, MV and LAD; ISRT + 3DCRT-LV, RV, MV, TV, and LA; ISRT + intensity modulated radiation therapy-LV and RV; ISRT + proton therapy-none. The following strong correlations were observed: IFRT-RA; ISRT + 3DCRT-LAD, RA, AV; ISRT + IMRT-LA, RA, LAD, AV, TV, and MV; ISRT + proton therapy-LV only. CONCLUSIONS: In the management of mediastinal lymphoma, more conformal treatment techniques can lead to more heterogeneous dose distributions across the heart, which translate into weaker relationships between mean heart dose and mean cardiac substructure doses. Consequently, models for assessing the risk of cardiac toxicity after radiation therapy that rely on MHD can be misleading when using modern treatment fields and techniques. Contouring the cardiac substructures and evaluating their dose is important when using contemporary RT.
Assuntos
Coração/efeitos da radiação , Linfoma/radioterapia , Neoplasias do Mediastino/radioterapia , Humanos , Dosagem RadioterapêuticaRESUMO
Most patients treated with proton therapy have had eye tumors, sarcomas, or, more recently, pediatric, or prostate cancers. As more proton centers have developed globally, increased capacity will permit exploration of other potential indications for proton therapy, including for the treatment of breast cancer. The rationale for proton therapy in the treatment of breast cancer is reduced inadvertent radiation dose to the heart and lung, as well as improved target coverage. As with any new technology, multiple technical parameters require optimization to deliver safe and effective radiation therapy and to maximize the benefits of the new technology. The purpose of this report is to provide a technical guide for the treatment of breast cancer with passive-scattering proton therapy and an algorithm for selecting patients with breast cancer who would benefit from proton therapy.
RESUMO
OBJECT: The authors conducted a study to assess the eye lens dosimetry in trigeminal neuralgia (TN) treatment when using the Leksell Gamma Knife model C. METHODS: Phantom studies were used to measure the maximal dose reaching the eye lens with and without eye shielding. Six consecutive patients with TN were evaluated for Gamma Knife surgery (GKS). The maximum prescribed dose of 80 Gy was delivered with a single shot using the 4-mm collimator helmet. High-sensitivity thermoluminescence dosimeter chips (TLDCs) were used to measure the dosimetry. In vitro, the Leksell GammaPlan (LGP) system predicted the mean maximal doses of 1.08 +/- 0.08 and 0.15 +/- 0.01 Gy (mean +/- standard deviation) to the lens ipsilateral to the treated trigeminal nerve without and with eye shielding, respectively. The TLDCs-measured dosimetry indicated the mean maximal doses of 1.12 +/- 0.09 and 0.17 +/- 0.01 Gy without and with eye shielding, respectively. The maximal doses to the lens contralateral to the nerve were similar. In vivo, the LGP predicted the mean maximal doses to the lens ipsilateral to the treated nerve as 1.1 +/- 0.07 and 0.16 +/- 0.02 Gy, respectively, without and with eye shielding. The dosimetry measured by TLDCs indicated the mean maximal dose to the lens ipsilateral to the treated nerve as 0.17 +/- 0.02 Gy with eye shielding. The mean maximal doses to the lens contralateral to the nerve were similar. Using the 110 and 125 degrees gamma angles, the LGP predicted the mean maximal doses of 0.32 +/- 0.04 and 0.12 +/- 0.04 Gy to the lens without and with eye shielding, respectively. CONCLUSIONS: Patients with TN undergoing GKS without eye shielding may develop cataracts due to the high radiation dose to the eye lenses. The authors suggest the routine use of bilateral eye shielding for the patients.
Assuntos
Raios gama , Cristalino/efeitos da radiação , Radiocirurgia/instrumentação , Neuralgia do Trigêmeo/cirurgia , Dispositivos de Proteção dos Olhos , Humanos , Modelos Neurológicos , Imagens de Fantasmas , Proteção Radiológica/instrumentação , Dosimetria TermoluminescenteRESUMO
PURPOSE: To compare dosimetric endpoints between proton therapy (PT) and conventional radiation and determine the feasibility of PT for regional nodal irradiation (RNI) in women with breast cancer. METHODS AND MATERIALS: From 2012 to 2014, 18 women (stage IIA-IIIB) requiring RNI prospectively enrolled on a pilot study. Median age was 51.8 years (range, 42-73 years). The cohort included breast-conserving therapy (BCT) and mastectomy patients and right- and left-sided cancers. Treatment targets and organs at risk were delineated on computed tomography scans, and PT and conventional plans were developed. Toxicity was prospectively recorded using Common Terminology Criteria for Adverse Events version 4.0. A Wilcoxon signed-rank sum test compared the dose-volume parameters. The primary endpoint was a reduction in cardiac V5. RESULTS: Median follow-up was 20 months (range, 2-31 months). For all patients, the PT plan better met the dosimetric goals and was used for treatment. Proton therapy alone was used for 10 patients (9 postmastectomy, 1 after BCT) and combined proton-photon in 8 (6 BCT, 2 postmastectomy with immediate expander reconstruction). Proton therapy improved coverage of level 2 axilla (P=.0005). Adequate coverage of internal mammary nodes was consistently achieved with PT (median D95, 50.3 Gy; range, 46.6-52.1 Gy) but not with conventional radiation therapy (median D95, 48.2 Gy; range, 40.8-55 Gy; P=.0005). Median cardiac V5 was 0.6% with PT and 16.3% with conventional radiation (P<.0001). Median ipsilateral lung V5 and V20 were improved with PT (median V5 35.3% vs 60.5% [P<.0001]; and median V20, 21.6% vs 35.5% [P<.0001]). Grade 3 dermatitis developed in 4 patients (22%), which was the only grade 3 toxicity. No grade 4+ toxicities developed. CONCLUSION: Proton therapy for RNI after mastectomy or BCT significantly improves cardiac dose, especially for left-sided patients, and lung V5 and V20 in all patients without excessive acute toxicity. Proton therapy simultaneously improves target coverage for the internal mammary nodes and level 2 axilla, which may positively impact long-term survival in breast cancer patients.
Assuntos
Coração/efeitos da radiação , Pulmão/efeitos da radiação , Irradiação Linfática/métodos , Órgãos em Risco/efeitos da radiação , Terapia com Prótons , Terapia com Prótons/métodos , Neoplasias Unilaterais da Mama/radioterapia , Adulto , Idoso , Axila , Estudos de Viabilidade , Feminino , Seguimentos , Coração/diagnóstico por imagem , Humanos , Pulmão/diagnóstico por imagem , Irradiação Linfática/efeitos adversos , Mastectomia , Pessoa de Meia-Idade , Órgãos em Risco/diagnóstico por imagem , Fótons/efeitos adversos , Fótons/uso terapêutico , Projetos Piloto , Cuidados Pós-Operatórios , Estudos Prospectivos , Terapia com Prótons/efeitos adversos , Prótons/efeitos adversos , Exposição à Radiação/prevenção & controle , Radiodermite/patologia , Radiografia , Dosagem Radioterapêutica , Fatores de Tempo , Neoplasias Unilaterais da Mama/diagnóstico por imagem , Neoplasias Unilaterais da Mama/patologiaRESUMO
OBJECTIVES: Regional node irradiation in patients with invasive breast cancer often results in increased radiation exposure to organs at risk. We evaluated the potential advantages of 3-dimensional conformal photon+proton therapy (3DCX+PT) in treating regional nodes versus photon-electron (3DCRT) or intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Ten left-sided breast cancer patients underwent radiation treatment planning. 3DCX+PT, 3DCRT, and IMRT plans were generated for each patient. RESULTS: There was no significant difference in target coverage between 3DCX+PT and IMRT. However, coverage of level II axillary lymph nodes was inferior with 3DCRT with a median D95 of 45 versus 50 Gy with either IMRT (P=0.0006) or 49.5 CGE with 3DCX+PT (P=0.0033). Internal mammary nodes coverage was also inferior with 3DCRT (median D95 was 42 Gy) compared with 47 Gy with IMRT (P=0.043) or 48.5 CGE with 3DCX+PT (P=0.0068).With 3DCX+PT, left lung V20 and V5 were 31% and 50% versus 36% (P=0.0368) and 70% (P=0.0007) with 3DCRT and 30% (P=0.7328) and 81% (P=0.0002) for IMRT. 3DCX+PT resulted in heart V20 and heart V5 of 0% and 7%, respectively, versus 4% (P=0.0067) and 24% (P=0.0002) with 3DCRT and 21% (P=0.0001), 50% (P=0.0001) with IMRT. The IMRT plans produced significantly higher integral, contralateral lung, and breast doses. CONCLUSIONS: Regional node target coverage was inferior with 3DCRT compared with either IMRT or 3DCX+PT. Organs at risk were exposed to less radiation with 3DCX+PT compared with 3DCRT or IMRT. Proton treatment offered both improved coverage of the regional lymph nodes and decreased dose to the heart, lung, and contralateral normal tissue.
Assuntos
Neoplasias da Mama/radioterapia , Linfonodos , Irradiação Linfática/métodos , Órgãos em Risco/efeitos da radiação , Terapia com Prótons/métodos , Radioterapia Conformacional/métodos , Axila , Neoplasias da Mama/patologia , Feminino , Humanos , Planejamento da Radioterapia Assistida por Computador , Radioterapia de Intensidade Modulada/métodosRESUMO
BACKGROUND: To assess the potential benefit of proton therapy (PT) over photon therapy, we compared 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and PT plans in patients undergoing neoadjuvant chemoradiation for resectable rectal cancer at our institution. METHODS: Eight consecutive patients with resectable (T2-T3) rectal cancers underwent 3DCRT, IMRT, and 3-dimensional conformal PT treatment planning. Initial target volumes (PTV1) were contoured using the Radiation Therapy Oncology Group anorectal atlas guidelines. Boost target volumes (PTV2) consisted of the gross rectal tumor plus a uniform 2-cm expansion. Plans delivered 45 Gray (Gy) or Cobalt Gray Equivalent (CGE) to the PTV1 and a 5.4-Gy (CGE) boost to the PTV2. Ninety-five percent of the PTVs received 100% of the target dose and 100% of the PTVs received 95% of the target dose. Standard normal-tissue constraints were utilized. Wilcoxon paired t-tests were performed to compare various dosimetric points between the 3 plans for each patient. RESULTS: All plans met all normal-tissue constraints and were isoeffective in terms of PTV coverage. The proton plans offered significantly reduced median normal-tissue exposure over the 3DCRT and IMRT plans with respect to pelvic bone marrow at the V5Gy, V10Gy, V15Gy, and V20Gy levels and the small bowel space at the V10Gy and V20Gy levels. The proton plans also offered significantly reduced median normal-tissue exposure over the 3DCRT plans with respect to the small bowel at the V30Gy and V40Gy levels and the urinary bladder at the V40Gy level. CONCLUSIONS: By reducing bone marrow exposure, PT may reduce the acute hematologic toxicity of neoadjuvant chemoradiation and increase the likelihood of uninterrupted chemotherapy delivery. Bone marrow sparing may also facilitate the delivery of salvage chemotherapy for patients who subsequently develop hematogenous metastasis. Reduced small bowel exposure using PT may also reduce toxicity and possibly facilitate the use of more-aggressive chemotherapy with radiotherapy.
RESUMO
In this case report, we present the history and treatment of a 70-year-old man with synchronous bilateral non-small-cell lung cancers with proton-beam radiation. Surgical treatment was not feasible and optimized photon intensity-modulated radiotherapy (IMRT) to the primary tumors would have resulted in unacceptably high normal-tissue exposures. Proton-beam radiation enabled radiation dose escalation and concurrent chemotherapy while maintaining normal-tissue tolerance.
RESUMO
Desmoid tumors are benign mesenchymal tumors with a strong tendency for local recurrence after surgery. Radiotherapy improves local control following incomplete resection, but nearby organs at risk may limit the dose to the target volume. The patient in this report presented with a recurrent desmoid tumor of the right flank and underwent surgery with microscopically positive margins. Particular problems presented in this case included that the tumor bed was situated in close proximity to the liver and the right kidney and that the right kidney was responsible for 65% of the patient's renal function. Intensity-modulated radiation therapy plans delivering 54 Gy necessarily exposed the right kidney to a V18 of 98% and the liver to a V30 of 55%. Proton therapy plans significantly reduced the right kidney V18 to 32% and the liver V30 to 28%. In light of this, the proton plan was utilized for treatment of this patient. Proton therapy was tolerated without gastrointestinal discomfort or other complaints. Twenty-four months after initiation of proton therapy, the patient is without clinical or radiographic evidence of disease recurrence. In this setting, the improved dose distribution associated with proton therapy allowed for curative treatment of a patient who arguably could not have been safely treated with intensity-modulated radiation therapy or other methods of conventional radiotherapy.
Assuntos
Fibromatose Abdominal/radioterapia , Fótons/uso terapêutico , Terapia com Prótons , Adulto , Feminino , Fibromatose Abdominal/patologia , Humanos , Planejamento da Radioterapia Assistida por Computador , Radioterapia de Intensidade ModuladaRESUMO
OBJECTIVE: The authors develop and introduce an adaptor in gamma knife radiosurgery to fix the Y/Z slides inside the Leksell coordinate G frame for the treatment of concomitant bilateral far-lateral intracranial lesions. CLINICAL PRESENTATION: The new adaptor was used to treat a 60-year-old woman with renal cell carcinoma and multiple brain metastases. She experienced sudden onset of left-sided weakness and disturbed consciousness. Brain computed tomographic scans showed a large right temporal intracerebral hematoma. After a craniectomy for the removal of the hematoma, she received a complete course of whole brain radiotherapy. However, several new tumors were detected on the follow-up brain magnetic resonance imaging scan. INTERVENTION: The longest distance of these far-lateral lesions on the x axis was approximately 108 mm. It was not possible to treat some of these tumors in one session with the normal use of the Y/Z slides in the trunnions mode. We developed a new adaptor to fix the Y/Z slides inside the G frame. By using the adaptor, the far-lateral located tumors were treated successfully in a single session. CONCLUSION: This newly developed adaptor can fix the Y/Z slides inside the G frame. It increases the range of the coordinates on the x axis from 52 to 148 mm to 30 to 170 mm. Using the adapter, gamma knife radiosurgery is a simple and accurate procedure for the treatment of bilateral far-lateral lesions in one session, particularly for lesions that cannot be approached with the normal use of the Y/Z slides in the trunnions mode.